COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00610129
Recruitment Status : Completed
First Posted : February 7, 2008
Results First Posted : November 20, 2015
Last Update Posted : November 20, 2015
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:

The purpose of this study is to test a new drug for neuroendocrine tumors. We think that this new drug may help control your tumor.

MK-0646 is a monoclonal antibody. An antibody is a protein that is able to attach to specific target on cancer cells. This target helps the cancer cells grow and divide. By attaching to the target, it may stop the cancer cells from further growth and dividing. This study will help find out if MK-0646 is a helpful drug when taken in patients with neuroendocrine tumor.

This study is a phase 2 study. The purpose of a phase 2 study is to find out what effects, good and/or bad, MK-0646 has on metastatic neuroendocrine tumors.

Condition or disease Intervention/treatment Phase
Neuroendocrine Tumors Metastatic Neuroendocrine Tumors Drug: MK-0646 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Study Start Date : January 2008
Actual Primary Completion Date : January 2010
Actual Study Completion Date : January 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Drug: MK-0646
MK-0646 (20 mg/mL) in sterilized solution for IV infusion (12.7 mL to deliver 12.0 mL) will be used for a dose of 10 mg/kg IV weekly administered over 60 minutes.

Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: 2 years ]
    in patients with metastatic carcinoid tumors and in metastatic islet cell tumors (parallel cohorts) when treated with MK-0646 alone.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with histologically or cytologically confirmed metastatic neuroendocrine tumors (NET)
  • Patients must have histologically or cytologically confirmed well differentiated (low to intermediate grade) neuroendocrine tumors. High grade or poorly differentiated (i.e., large or small cell variant), Merkel cell, medullary carcinoma of the thyroid, and adrenal gland malignancies (including paragangliomas) are excluded from this study.
  • Patient has at least one measurable lesion greater than or equal to 20 mm or greater than 10 mm on spiral CT.
  • Patients who are on therapy with a somatostatin analogue are eligible for entry but must be on a stable dose for at least 3 months with no evidence of tumor shrinkage during that time period.
  • Patient is male or female.
  • Patient ≥ or equal to 18 years of age on the day of signing informed consent.
  • Patient has performance status 0-2 on the ECOG Performance Scale.
  • Patient has adequate organ function as indicated by the following laboratory values:
  • Absolute Neutrophil Count (ANC) ≥ than or equal to 1,500/mcL
  • platelets ≥ than or equal to 100,000/mcL
  • Hemoglobin ≥ than or equal to 8 g/dL
  • Serum Creatinine ≤ than or equal to 2 times the upper limit of normal (ULN)/ OR calculated CrCl ≥ than or equal to 60 mL/min (patients with creatinine levels ≥ than or equal to 2 times the ULN only). Patient may not be on dialysis
  • Serum total bilirubin ≤ than or equal to 1.5 times the ULN
  • AST (SGOT) and ALT (SGPT) ≤ than or equal to 5 times the ULN
  • Prothrombin time (PT) Partial Thromboplastin time (PTT)
  • ≤ than or equal to 1.2 times the ULN
  • ≤than or equal to 1.2 times the ULN Creatinine clearance should be calculated by the Cockcroft-Gault method as follows:
  • Male creatinine clearance = (140-age) x (weight in Kg)/(serum Cr x 72)
  • Female creatinine clearance = ((140- age) x (weight in Kg)/(serum Cr x 72)) x 0.85
  • Patient, or patient's legal representative, has voluntarily agreed to participate by giving written informed consent.
  • Previous local therapy (e.g. chemoembolization or bland embolization) is allowed if completed > 6 weeks prior to study entry. For patients who received local therapy prior to study entry, there must be either documented growth of measurable disease within the embolization field or outside of the embolization field, or both, prior to study entry if the area of the embolization field was the only site of measurable disease.
  • Previous chemotherapy, radiotherapy, and/or biologic therapy, including investigational agents, is/are allowed if completed > 4 weeks prior to study entry (>6 weeks if last regimen contained BCNU or mitomycin C, and > 6 weeks from last dose of radiation therapy or radiopharmaceutical.
  • Patients must not have disease that is currently amenable to curative surgery. Prior surgery is allowed no less than 6 weeks prior to study entry.
  • Patients with diabetes mellitus are eligible for study entry but must have controlled diabetes as defined by hemoglobin A1c <8.0% within 2 weeks of initiation of protocol therapy.

Exclusion Criteria:

  • Patient has toxicities from prior therapies that have not resolved to grade 1 or grade 0.
  • Patient has known CNS metastases and/or carcinomatous meningitis.
  • Patient has known primary central nervous system tumor.
  • Patient has a known hypersensitivity to the components of study drug (MK-0646) or its analogs that is not treatable by premedication with antihistamines and steroids.
  • Patient has a condition, including but not limited to, serious active infection, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, or major psychiatric illness, which, in the opinion of the treating investigator, is likely to confound the results of the study, or makes participation not in the best interest of the patient.
  • Patient has a history of a prior active malignancy within the past 5 years, with the exception of cervical intraepithelial neoplasia; basal cell carcinoma of the skin, adequately treated localized prostate carcinoma with PSA <1.0, or squamous cell carcinoma of the skin removed (or the more superficial keratoacanthoma).
  • Patient has known psychiatric or substance abuse disorders that would, in the opinion of the treating investigator, interfere with cooperation with the requirements of the trial.
  • Patient is breastfeeding or pregnant (this will requires a negative test within 72 hours of initiation of therapy), or expecting to conceive within the projected duration of the study.
  • Patient is not using adequate contraception.
  • Patient is known to be Human Immunodeficiency Virus (HIV)-positive.
  • Patient has known active Hepatitis B or C.
  • Patient is concurrently using growth hormone (GH), or growth hormone inhibitors.
  • Patient has prior treatment with IGF-1R inhibitors.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00610129

Layout table for location information
United States, New Jersey
Memorial Sloan-Kettering at Basking Ridge
Basking Ridge, New Jersey, United States, 07920
United States, New York
Memorial Sloan-Kettering Cancer Center @ Suffolk
Commack, New York, United States, 11725
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Memorial Sloan-Kettering Cancer Center at Mercy Medical Center
Rockville Centre, New York, United States, 11570
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
Sleepy Hollow, New York, United States, 10591
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme Corp.
Layout table for investigator information
Principal Investigator: Leonard Saltz, MD Memorial Sloan Kettering Cancer Center
Additional Information:
Layout table for additonal information
Responsible Party: Memorial Sloan Kettering Cancer Center Identifier: NCT00610129    
Other Study ID Numbers: 07-162
First Posted: February 7, 2008    Key Record Dates
Results First Posted: November 20, 2015
Last Update Posted: November 20, 2015
Last Verified: October 2015
Keywords provided by Memorial Sloan Kettering Cancer Center:
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue